Deferasirox Novartis.
Novartis is developing a chelating agent, deferasirox, as a once-daily oral therapy for the potential treatment of chronic iron overload in patients needing blood transfusions. By December 2004, data from a phase III trial for iron overload had been released, and filing is expected in the US and EU in the first half of 2005.